Drugs / SP Shz TIV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03344029 | Nov 2017 → May 2018 | influenza | Sanofi | Completed | Met primary |
| Phase 4 | NCT02228980 | Sep → Dec 2014 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP Shz-TIV | “trivalent influenza vaccine (split-virion, inactivated) produced at Shenzhen (SP Shz TIV)” NCT02228980 ↗ |
| Known as | Shz-IIV3 | “Since 2013, Sanofi Pasteur's facilities in Shenzhen, China have produced a trivalent inactivated influenza vaccine (Shz-IIV3) for each influenza season according to Chinese...” PMID 30779689 ↗ Apr 2019 |
| Modality | Vaccine | “trivalent influenza vaccine (split-virion, inactivated)” NCT02228980 ↗ |
| Route | Intramuscular | “0.25 mL Intramuscular (2 doses given 28 days apart)” NCT02228980 ↗ |